Trial Profile
Investigating Meningococcal Vaccines in Adults - An Exploratory, Open-label, Immunogenicity Study of a Licensed Meningococcal Capsular Group B Vaccine (4CMenB, Bexsero) in Adults
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Nov 2021
Price :
$35
*
At a glance
- Drugs Meningococcal vaccine group B (Primary)
- Indications Meningococcal group B infections
- Focus Pharmacodynamics
- 26 Oct 2021 Status changed from active, no longer recruiting to completed.
- 17 Oct 2018 Planned End Date changed from 1 Apr 2018 to 30 Apr 2019.
- 29 Sep 2017 Planned End Date changed from 1 Apr 2017 to 1 Apr 2018.